structure of Ethyl 3,5-Dichloroimidazo[1,2-a]pyridine-2-carboxylate

Ethyl 3,5-Dichloroimidazo[1,2-a]pyridine-2-carboxylate

CAS No.: 1000018-01-8
M. Wt: 259.089
M. Fa: C10H8Cl2N2O2
InChI Key: ZVCJPYORUMKIEO-UHFFFAOYSA-N

Names and Identifiers of 1000018-01-8

CAS Number

1000018-01-8

MDL Number

MFCD09842623

IUPAC Name

ethyl 3,5-dichloroimidazo[1,2-a]pyridine-2-carboxylate

InChI

InChI=1S/C10H8Cl2N2O2/c1-2-16-10(15)8-9(12)14-6(11)4-3-5-7(14)13-8/h3-5H,2H2,1H3

InChIKey

ZVCJPYORUMKIEO-UHFFFAOYSA-N

Canonical SMILES

CCOC(=O)C1=C(N2C(=N1)C=CC=C2Cl)Cl

UNSPSC Code

12352100

Physical and chemical properties of 1000018-01-8

Density

1.5±0.1 g/cm3

Exact Mass

257.996277

Index of Refraction

1.630

LogP

3.29

Molecular Formula

C10H8Cl2N2O2

Molecular Weight

259.089

Safety Information of 1000018-01-8

Pictograms

Signal Word

 Warning

Safety Data Sheet
Supports customized editing of SDS information and downloading in PDF documents.

Applications of 1000018-01-8

Ethyl 3,5-Dichloroimidazo[1,2-a]pyridine-2-carboxylate has potential applications in various fields:

  • Pharmaceuticals: Due to its biological activity against resistant bacterial strains and cancer cells, it may serve as a lead compound in drug development.
  • Chemical Research: Its unique structure makes it a valuable intermediate for synthesizing other complex organic molecules.

Interaction Studies of 1000018-01-8

Interaction studies involving Ethyl 3,5-Dichloroimidazo[1,2-a]pyridine-2-carboxylate focus on its binding affinity to specific biological targets such as kinases and bacterial enzymes. Molecular docking studies have shown that this compound can effectively bind to active sites of target proteins, suggesting mechanisms for its biological activity .

Biological Activity of 1000018-01-8

Ethyl 3,5-Dichloroimidazo[1,2-a]pyridine-2-carboxylate has demonstrated significant biological activity. Research indicates that compounds within the imidazo[1,2-a]pyridine class exhibit antimicrobial properties, particularly against multidrug-resistant strains of tuberculosis. For instance, some derivatives have shown minimum inhibitory concentrations (MIC) as low as 0.03 μM against Mycobacterium tuberculosis . Additionally, studies suggest that these compounds may inhibit specific kinases involved in cancer pathways, making them potential candidates for anticancer therapies .